Multiple sclerosis (MS) is considered an immune disease of the central nervous system, and the most important effective therapies are based on drugs which are able to modify the systemic immune system (immunomodulating and immunosuppressant agents)
Could autologous hematopoietic stem cell transplantation be considered a second-line treatment option in relapsing-remitting multiple sclerosis? A critical editorial
D’Amico, EmanueleConceptualization
;
2017-01-01
Abstract
Multiple sclerosis (MS) is considered an immune disease of the central nervous system, and the most important effective therapies are based on drugs which are able to modify the systemic immune system (immunomodulating and immunosuppressant agents)File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
